嵌合基因与恶性肿瘤的研究进展

doi:10.3969/j.issn.1000-8535.2023.11.001

广州医药 ›› 2023, Vol. 54 ›› Issue (11): 1-10.DOI: 10.3969/j.issn.1000-8535.2023.11.001

• 专家综述 • 下一篇

嵌合基因与恶性肿瘤的研究进展

余咏晖^1,2, 黄红梅¹, 匡新杰¹, 卢文菊², 吕嘉春¹, 丘福满¹

1 广州医科大学公共卫生学院（广东广州 511436）
2 广州医科大学,广州呼吸健康研究院,呼吸疾病全国重点实验室（广东广州 510180）

收稿日期:2023-07-30 出版日期:2023-11-20 发布日期:2023-12-12
通讯作者: 丘福满,E-mail：fumanqiu@gzhmu.edu.cn
作者简介:丘福满医学博士,副教授,博士生导师; 现任广东省热带医学学会理事、广东省流行病学会青年委员会常务委员; 广州市高层次人才青年后备人才,国家自然科学基金及广东省自然科学基金项目通讯评审专家,广东省新冠病毒疫苗预防接种异常反应调查诊断专家组专家; 担任BMC Cancer、BMC Medical Genetics、Technology in Cancer Research & Treatment等杂志的编委会成员、审稿人; 一直从事肿瘤分子流行病学、易感基因、生物标志物及生物统计学方法应用等领域的工作,在复杂疾病的遗传易感机制及表观遗传修饰等领域有较好的研究基础; 近年来主持国家自然科学基金项目2项和省市级课题3项,研究成果以通讯作者或第一作者等在Clin Cancer Res,Plos genet等国际著名刊物发表SCI研究论文40多篇,其中第一作者或通讯作者≥15篇; 参编论著《肿瘤分子流行病学》和本科教材《预防医学：案例版》各1部; 获得国家授权发明专利2项（2020年,2021年）; 获教育部高等学校优秀成果奖自然科学奖二等奖1项（2017年）; 余咏晖和黄红梅为共同第一作者
基金资助:
国家自然科学基金面上项目（81872127）

Advances in the study of chimeric genes in malignant tumors

YU Yonghui^1,2, HUANG Hongmei¹, KUANG Xinjie¹, LU Wenju², LV Jiachun¹, QIU Fuman¹

1 School of Public Health,Guangzhou Medical University,Guangzhou 511436,China;
2 State Key Laboratory of Respiratory Disease,Guangzhou Institute of Respiratory Health,Guangzhou Medical University,Guangzhou 510180,China

Received:2023-07-30 Online:2023-11-20 Published:2023-12-12

摘要/Abstract

摘要： 嵌合基因是指由两个或多个原本不连续的基因片段重组而成的新基因,它们可以通过基因组重排、转录诱导等机制产生。嵌合基因在正常生理和发育过程中具有重要的功能和调控作用。嵌合基因可以改变原有基因的表达水平、编码蛋白质的结构和功能、信号通路的激活和抑制等,从而促进肿瘤细胞的增殖、侵袭、转移和耐药性。近年来,随着高通量测序技术的发展和应用,越来越多的嵌合基因被发现和鉴定,它们在不同类型的肿瘤中具有不同的表达模式和功能作用,为肿瘤的分子诊断、预后评估和靶向治疗提供了新的机会和挑战。本文旨在对嵌合基因产生的机制、检测方法和在肿瘤中的功能和应用等方面进行综述,为进一步认识嵌合基因在肿瘤进展中的功能机制及其精准化治疗提供参考。

关键词: 嵌合基因, 恶性肿瘤, 形成机制, 诊断治疗

Abstract: Chimeric genes refer to novel genes formed by the recombination of two or more originally non-contiguous gene fragments through mechanisms like genomic rearrangement and transcriptional induction．They play important roles in physiological and developmental regulation．Chimeric genes can alter the expression,structure and function of original genes,modulate signaling pathway activation and inhibition,and thereby promote tumor cell proliferation,invasion,metastasis and drug resistance．In recent years,with the development and application of high-throughput sequencing technologies,increasing numbers of chimeric genes have been discovered and identified．They demonstrate different expression patterns and functional roles in various tumor types,providing new opportunities and challenges for molecular diagnosis,prognostic assessment and targeted therapy of cancers．This review summarizes the mechanisms of chimeric gene formation,detection methods and their functions and applications in tumors,to provide insights into the functional mechanisms of chimeric genes in tumor progression and their implications for precision treatment．

Key words: chimeric gene, malignant tumors, formation mechanisms, diagnosis and treatment

余咏晖, 黄红梅, 匡新杰, 卢文菊, 吕嘉春, 丘福满. 嵌合基因与恶性肿瘤的研究进展[J]. 广州医药, 2023, 54(11): 1-10.

YU Yonghui, HUANG Hongmei, KUANG Xinjie, LU Wenju, LV Jiachun, QIU Fuman. Advances in the study of chimeric genes in malignant tumors[J]. Guangzhou Medical Journal, 2023, 54(11): 1-10.

参考文献

[1] HANAHAN D.Hallmarks of Cancer:New Dimensions[J].Cancer Discov,2022,12(1):31-46.
[2] KOHSAKA S,HAYASHI T,NAGANO M,et al.Identification of novel CD74-NRG2alpha fusion from comprehensive profiling of lung adenocarcinoma in Japanese never or light smokers[J].J Thorac Oncol,2020,15(6):948-961.
[3] LI W,GUO L,LIU Y,et al.Potential unreliability of uncommon ALK,ROS1,and RET genomic breakpoints in predicting the efficacy of targeted Therapy in NSCLC[J].J Thorac Oncol,2021,16(3):404-418.
[4] XIE Z Q,BABICEANU M,KUMAR S,et al.Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma[J].PNatl Acad Sci USA,2016,113(46):13126-13131.
[5] AKIVA P,TOPORIK A,EDELHEIT S,et al.Transcription-mediated gene fusion in the human genome[J].Genome Res,2006,16(1):30-36.
[6] WU H,LI X,LI H.Gene fusions and chimeric RNAs,and their implications in cancer[J].Genes Dis,2019,6(4):385-390.
[7] CHWALENIA K,FACEMIRE L,LI H.Chimeric RNAs in cancer and normal physiology[J].Wiley Interdiscip Rev RNA,2017,8(6).
[8] CORTES J E,GAMBACORTI-PASSERINI C,DEININGER M W,et al.Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia:results from the randomized BFORE trial[J].J Clin Oncol,2018,36(3):231-237.
[9] PANAGOPOULOS I,HEIM S.Neoplasia-associated chromosome translocations resulting in gene truncation[J].Cancer Genomics Proteomics,2022,19(6):647-672.
[10] ZHANG Y,GONG M,YUAN H,et al.Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation[J].Cancer Discov,2012,2(7):598-607.
[11] DAI X,THEOBARD R,CHENG H,et al.Fusion genes:A promising tool combating against cancer[J].Biochim Biophys Acta Rev Cancer,2018,1869(2):149-160.
[12] SUN Y,LI H.Chimeric RNAs discovered by RNA sequencing and their roles in cancer and rare genetic diseases[J].Genes(Basel),2022,13(5):741.
[13] SHOSHANI O,BRUNNER S F,YAEGER R,et al.Chromothripsis drives the evolution of gene amplification in cancer[J].Nature,2021,591(7848):137-141.
[14] BOER J M,DEN BOER M L.BCR-ABL1-like acute lymphoblastic leukaemia:From bench to bedside[J].Eur J Cancer,2017(82):203-218.
[15] RABBITTS T H.Chromosomal translocations in human cancer[J].Nature,1994,372(6502):143-149.
[16] SODA M,CHOI Y L,ENOMOTO M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561-566.
[17] XIAO S,NALABOLU S R,ASTER J C,et al.FGFR1 is fused with a novel zinc-finger gene,ZNF198,in the t(8;13)leukaemia/lymphoma syndrome[J].Nat Genet,1998,18(1):84-87.
[18] KO J M,CHEUNG M H,KWAN M W,et al.Genomic instability and alterations in Apc,Mcc and Dcc in Hong Kong patients with colorectal carcinoma[J].Int J Cancer,1999,84(4):404-409.
[19] ZOMA M,CURTI L,SHINDE D,et al.EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer[J].Nat Commun,2021,12(1):4147.
[20] LU G,WU J,ZHAO G,et al.Abundant and broad expression of transcription-induced chimeras and protein products in mammalian genomes[J].Biochem Biophys Res Commun,2016,470(3):759-765.
[21] SINGH D,CHAN J M,ZOPPOLI P,et al.Transforming fusions of FGFR and TACC genes in human glioblastoma[J].Science,2012,337(6099):1231-1235.
[22] LEI Q,LI C,ZUO Z,et al.Evolutionary insights into RNA trans-splicing in vertebrates[J].Genome Biol Evol,2016,8(3):562-577.
[23] NACU S,YUAN W,KAN Z,et al.Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples[J].BMC Med Genomics,2011(4):11.
[24] PRAKASH T,SHARMA V K,ADATI N,et al.Expression of conjoined genes:another mechanism for gene regulation in eukaryotes[J].PLoS One,2010,5(10):e13284.
[25] LI H,WANG J,MA X,et al.Gene fusions and RNA trans-splicing in normal and neoplastic human cells[J].Cell Cycle2009,8(2):218-222.
[26] WANG Y,ZOU Q,LI F,et al.Identification of the cross-strand chimeric RNAs generated by fusions of bi-directional transcripts[J].Nat Commun,2021,12(1):4645.
[27] DORNEY R,DHUNGEL B P,RASKO J E J,et al.Recent advances in cancer fusion transcript detection[J].Brief Bioinform,2023,24(1):bbac 519.
[28] LI Z,QIN F,LI H.Chimeric RNAs and their implications in cancer[J].Curr Opin Genet Dev,2018(48):36-43.
[29] STANGL C,DE BLANK S,RENKENS I,et al.Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing[J].Nat Commun,2020,11(1):2861.
[30] CHENG Y W,CHEN Y M,ZHAO Q Q,et al.Long read single-molecule real-time sequencing elucidates transcriptome-wide heterogeneity and complexity in esophageal squamous cells[J].Front Genet,2019(10):915.
[31] MUKHERJEE S,MUKHERJEE S B,FRENKEL-MORGENSTERN M.Functional and regulatory impact of chimeric RNAs in human normal and cancer cells[J].Wiley Interdiscip Rev RNA,2023,14(5):e1777.
[32] NECKLES C,SUNDARA RAJAN S,CAPLEN N J.Fusion transcripts:Unexploited vulnerabilities in cancer?[J].Wiley Interdiscip Rev RNA,2020,11(1):e1562.
[33] DAMAYANTI N P,BUDKA J A,KHELLA H W Z,et al.Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma[J].Clin Cancer Res,2018,24(23):5977-5989.
[34] DELLIAUX C,TIAN T V,BOUCHET M,et al.TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases[J].Cancer Lett,2018(438):32-43.
[35] WANG Z,GUAN W,WANG M,et al.AML1-ETO inhibits acute myeloid leukemia immune escape by CD48[J].Leuk Lymphoma,2021,62(4):937-943.
[36] BRAUN T P,EIDE C A,DRUKER B J.Response and resistance to BCR-ABL1-targeted therapies[J].cancer cell,2020,37(4):530-542.
[37] GORTHI A,ROMERO J C,LORANC E,et al.EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma[J].Nature,2018,555(7696):387-391.
[38] LIQUORI A,IBANEZ M,SARGAS C,et al.Acute promyelocytic leukemia:A constellation of molecular events around a single PML-RARA fusion gene[J].cancers(Basel),2020,12(3):624.
[39] JAIN S,ABRAHAM A.BCR-ABL1-like B-Acute lymphoblastic leukemia/lymphoma:A comprehensive review[J].Arch Pathol Lab Med,2020,144(2):150-155.
[40] SHARMA N,MAGISTRONI V,PIAZZA R,et al.BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene[J].Mol Cancer,2015(14):132.
[41] ELSHATLAWY M,SAMPSON J,CLARKE K,et al.EML4-ALK biology and drug resistance in non-small cell lung cancer:a new phase of discoveries[J].Mol Oncol,2023,17(6):950-963.
[42] SINGH S,ABU-ZAID A,JIN H,et al.Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma[J].Sci Transl Med,2022,14(653):eabq2096.
[43] LINARDIC C M.PAX3-FOXO1 fusion gene in rhabdomyosarcoma[J].Cancer Lett,2008,270(1):10-18.
[44] CAI C,WANG H,HE H H,et al.ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer[J].J Clin Invest,2013,123(3):1109-1122.
[45] MAZZU Y Z,LIAO Y,NANDAKUMAR S,et al.Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity[J].Mol Oncol,2022,16(13):2451-2469.
[46] REJESKI K,DUQUE-AFONSO J,LUBBERT M.AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms[J].Oncogene,2021,40(38):5665-5676.
[47] MANI R S,IYER M K,CAO Q,et al.TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers[J].Cancer Res,2011,71(16):5387-5392.
[48] SELVANATHAN S P,GRAHAM G T,ERKIZAN H V,et al.Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing[J].Proc Natl Acad Sci U S A,2015,112(11):E1307-16.
[49] JABBOUR E,KANTARJIAN H.Chronic myeloid leukemia:2022 update on diagnosis,therapy,and monitoring[J].Am J Hematol,2022,97(9):1236-1256.
[50] YANG Z,YU L,WANG Z.PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer[J].Chin J Cancer Res,2016,28(1):65-71.
[51] RIGGI N,SUVA M L,STAMENKOVIC I.Ewing's Sarcoma[J].N Engl J Med,2021,384(2):154-164.
[52] ROSSI V,LEVATI L,BIONDI A.Diagnosis and monitoring of PML-RARA-positive acute promyelocytic leukemia by qualitative RT-PCR[J].Methods Mol Med,2006(125):115-126.
[53] GUO W,ZHU Y,PU X,et al.Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma[J].Front Oncol,2023(13):1116648.
[54] VITALE S R,RUIGROK-RITSTIER K,TIMMERMANS A M,et al.The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer[J].BMC Cancer,2022,22(1):165.
[55] BARWICK B G,ABRAMOVITZ M,KODANI M,et al.Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts[J].Br J Cancer,2010,102(3):570-576.
[56] SHAW A T,YEAP B Y,SOLOMON B J,et al.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement:a retrospective analysis[J].Lancet Oncol,2011,12(11):1004-1012.
[57] KURAVI S,CHENG J,FANGMAN G,et al.Preclinical evaluation of gilteritinib on NPM1-ALK-Driven anaplastic large cell lymphoma cells[J].Mol Cancer Res,2021,19(5):913-920.
[58] GROUP P T C,CALABRESE C,DAVIDSON N R,et al.Genomic basis for RNA alterations in cancer[J].Nature,2020,578(7793):129-136.
[59] KUMAR-SINHA C,KALYANA-SUNDARAM S,CHINNAIYAN A M.Landscape of gene fusions in epithelial cancers:seq and ye shall find[J].Genome Med,2015(7):129.

嵌合基因与恶性肿瘤的研究进展

Advances in the study of chimeric genes in malignant tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

[1]	英嵩崧, 高志岩. 肝内胆管细胞癌诊治进展[J]. 广州医药, 2023, 54(6): 100-105.
[2]	莫称龙, 赖海岸, 胡桂和, 莫泽珣, 黄晓梅, 侯乐, 魏树全. 三重多原发恶性肿瘤病例分析[J]. 广州医药, 2023, 54(1): 34-38.
[3]	侯泽鑫, 李军, 李思源, 蔺茹君, 冀雪姣, 向清淋. 2型糖尿病合并消化道恶性肿瘤患者的临床特征及影响因素分析[J]. 广州医药, 2020, 51(6): 57-61.
[4]	王秋明, 李亮, 张锦丰, 吴静娜. 30岁及以下乳腺癌术后首次复发转移特点分析[J]. 广州医药, 2020, 51(1): 50-54.
[5]	林颖欣, 庞丹梅, 胡倩, 段海波, 李财枝. D-二聚体在女性恶性肿瘤病情监测中的应用价值[J]. 广州医药, 2019, 50(2): 28-33.
[6]	谭小燕, 尹龙燕, 李凌. 乳腺恶性肿瘤患者诊断及治疗方法动态变化[J]. 广州医药, 2018, 49(1): 18-21.
[7]	王锋垲, 刘通, 冯丽丽. 老年晚期恶性肿瘤患者给予营养支持对癌因性疲倦、厌食行为影响[J]. 广州医药, 2018, 49(1): 62-64.
[8]	卢润豪. 术中及术前化疗干预对进展期胃恶性肿瘤手术患者p53、ki-67表达及预后影响的比较[J]. 广州医药, 2017, 48(5): 6-8.
[9]	邹传伟, 王小拍, 周丽霞. EGFR基因突变与肿瘤标志物检测在肺部占位病变鉴别诊断中的价值研究[J]. 广州医药, 2017, 48(3): 1-6.
[10]	邝俊. 彩色多普勒超声在乳腺良恶性肿瘤鉴别诊断中的应用价值[J]. 广州医药, 2017, 48(1): 56-58.
[11]	李晓虹, 李安群, 沈雪歌, 汤惠茹, 杨瑞, 刘铮, 申东兰, 吴瑞芳. 年轻女性恶性肿瘤化疗临床分析[J]. 广州医药, 2016, 47(1): 18-19.